{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:31:17Z","timestamp":1794976277717,"version":"4.9.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the prevalence and clinical associations of anti-C1q antibodies in IgG4-related disease (IgG4-RD), focusing on renal involvement and cutaneous small-vessel vasculitis (CSVV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled patients who met the revised 2020 Comprehensive Diagnostic Criteria and\/or the 2019 ACR\/EULAR Classification Criteria for IgG4-RD. Variables included demographics, organ involvement, clinical phenotypes, disease activity, serum biomarkers, follow-up duration, remission and relapses. Anti-C1q antibodies were measured using a quantitative enzyme-linked immunosorbent assay (cut-off &amp;lt;10 U\/ml).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy patients with a mean age of 52.1\u2009years were included. Thirty-four patients (48.6%) were male. Anti-C1q antibodies were positive in 74.3%, with a median level of 19.8 U\/ml. Patients with active disease had higher anti-C1q antibody levels than inactive patients (P = 0.03). Renal involvement was more frequent in anti-C1q positive patients (P = 0.01). Six patients (8.6%) had CSVV, and all had positive anti-C1q levels. All exhibited palpable purpura and one patient had urticarial-like lesions. These patients had multi-organ involvement, and most had high IgG, IgG1, IgG4 and hypocomplementemia. Skin biopsies in three patients showed leukocytoclastic vasculitis with lymphocytic and eosinophilic infiltrates. Anti-C1q antibody levels correlated negatively with levels of C3 and C4, and positively with levels of IgG1, IgG4, and serum free light chains. Anti-C1q positivity did not predict relapse-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study is the first to evaluate anti-C1q antibodies in IgG4-RD, finding a high prevalence, particularly in patients with renal involvement and CSVV. The results support the hypothesis that immune complex-mediated complement activation contributes to IgG4-RD pathogenesis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf020","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:21:09Z","timestamp":1736454069000},"page":"3701-3709","source":"Crossref","is-referenced-by-count":6,"title":["Anti-C1q antibodies in IgG4-related disease are common and associated with renal involvement and cutaneous small-vessel vasculitis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-1269","authenticated-orcid":false,"given":"Eduardo","family":"Mart\u00edn-Nares","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n , Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Nu\u00f1ez-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n , Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-0391","authenticated-orcid":false,"given":"Gabriela","family":"Hern\u00e1ndez-Molina","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n , Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025052703530244900_keaf020-B1","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-related disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025052703530244900_keaf020-B2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.55563\/clinexprheumatol\/qq9qup","article-title":"Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners","volume":"40(Suppl 134)","author":"Iaccarino","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025052703530244900_keaf020-B3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/RHU.0000000000001858","article-title":"Clinical and serological features in Latin American IgG4-related disease patients differ according to sex, ethnicity, and clinical phenotype","volume":"28","author":"Mart\u00edn-Nares","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025052703530244900_keaf020-B4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13075-017-1467-x","article-title":"New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases","volume":"19","author":"Yamada","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025052703530244900_keaf020-B5","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025052703530244900_keaf020-B6","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1136\/ard-2024-225846","article-title":"Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related disease","volume":"83","author":"Katz","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703530244900_keaf020-B7","first-page":"61","article-title":"The immunobiology of immunoglobulin G4 and complement activation pathways in IgG4-related disease","volume":"401","author":"Kawa","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"2025052703530244900_keaf020-B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.mpa.0000188308.75043.e4","article-title":"Autoimmune pancreatitis and complement activation system","volume":"32","author":"Muraki","year":"2006","journal-title":"Pancreas"},{"key":"2025052703530244900_keaf020-B9","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1136\/annrheumdis-2018-213705","article-title":"Serum complement factor C5a in IgG4-related disease","volume":"78","author":"Fukui","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025052703530244900_keaf020-B10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molimm.2015.05.010","article-title":"C1q, antibodies and anti-C1q autoantibodies","volume":"68","author":"Beurskens","year":"2015","journal-title":"Mol Immunol"},{"key":"2025052703530244900_keaf020-B11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.humpath.2018.07.008","article-title":"Role of complement system in patients with biopsy-proven immunoglobulin G4-related kidney disease","volume":"81","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"key":"2025052703530244900_keaf020-B12","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.ekir.2024.05.011","article-title":"Clinicopathologic features of IgG4-related kidney disease","volume":"9","author":"Buglioni","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025052703530244900_keaf020-B13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/01.pas.0000213331.09864.2c","article-title":"Autoimmune pancreatitis: a systemic immune complex mediated disease","volume":"30","author":"Deshpande","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2025052703530244900_keaf020-B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00296-009-1030-4","article-title":"Proteomics analysis in 28 patients with systemic IgG4-related plasmacytic syndrome","volume":"30","author":"Yamamoto","year":"2010","journal-title":"Rheumatol Int"},{"key":"2025052703530244900_keaf020-B15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025052703530244900_keaf020-B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025052703530244900_keaf020-B17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An international multispecialty validation study of the IgG4-related disease responder index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025052703530244900_keaf020-B18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025052703530244900_keaf020-B19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2025052703530244900_keaf020-B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/modpathol.2012.196","article-title":"Clinicopathologic analysis of IgG4-related skin disease","volume":"26","author":"Sato","year":"2013","journal-title":"Mod Pathol"},{"key":"2025052703530244900_keaf020-B21","doi-asserted-by":"crossref","first-page":"1410032","DOI":"10.3389\/fimmu.2024.1410032","article-title":"Anti-C1q antibodies: a biomarker for diagnosis and management of lupus nephritis. A narrative review","volume":"15","author":"Calatroni","year":"2024","journal-title":"Front Immunol"},{"key":"2025052703530244900_keaf020-B22","first-page":"19","article-title":"IgG and IgA autoantibodies to C1q in systemic and renal diseases","volume":"10","author":"Siegert","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"2025052703530244900_keaf020-B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/03009740701218717","article-title":"Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases","volume":"36","author":"Braun","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"2025052703530244900_keaf020-B24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0165-2478(00)00287-X","article-title":"Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases","volume":"75","author":"Horv\u00e1th","year":"2001","journal-title":"Immunol Lett"},{"key":"2025052703530244900_keaf020-B25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2249.2006.03153.x","article-title":"Anti-C1q antibodies in hepatitis C virus infection","volume":"145","author":"Saadoun","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"2025052703530244900_keaf020-B26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/14397595.2015.1076924","article-title":"Possible participation of IgG4 in the activation of complement in IgG4-related disease with hypocomplementemia","volume":"26","author":"Sugimoto","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025052703530244900_keaf020-B27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025052703530244900_keaf020-B28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-021-02481-3","article-title":"Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study","volume":"23","author":"Peng","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025052703530244900_keaf020-B29","doi-asserted-by":"crossref","first-page":"1087532","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front Immunol"},{"key":"2025052703530244900_keaf020-B30","doi-asserted-by":"crossref","first-page":"e140453","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"2025052703530244900_keaf020-B31","doi-asserted-by":"crossref","first-page":"952235","DOI":"10.3389\/fimmu.2022.952235","article-title":"The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly IgG4 in membranous nephropathy","volume":"13","author":"Manral","year":"2022","journal-title":"Front Immunol"},{"key":"2025052703530244900_keaf020-B32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2018.00639","article-title":"Complement activation in inflammatory skin diseases","volume":"9","author":"Giang","year":"2018","journal-title":"Front Immunol"},{"key":"2025052703530244900_keaf020-B33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molimm.2013.05.009","article-title":"Autoantibodies against complement components and functional consequences","volume":"56","author":"Dragon-Durey","year":"2013","journal-title":"Mol Immunol"},{"key":"2025052703530244900_keaf020-B34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1172\/JCI200421075","article-title":"Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes","volume":"114","author":"Trouw","year":"2004","journal-title":"J Clin Invest"},{"key":"2025052703530244900_keaf020-B35","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2015-310336","article-title":"Pathogenicity of IgG in patients with IgG4-related disease","volume":"65","author":"Shiokawa","year":"2016","journal-title":"Gut"},{"key":"2025052703530244900_keaf020-B36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaci.2021.05.002","article-title":"Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease","volume":"149","author":"Jarrell","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025052703530244900_keaf020-B37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.41140","article-title":"Disease severity linked to increase in autoantibody diversity in IgG4-related disease","volume":"72","author":"Liu","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025052703530244900_keaf020-B38","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1093\/rheumatology\/keab124","article-title":"What is the meaning of ANCA positivity in IgG4-related disease?","volume":"60","author":"Mart\u00edn-Nares","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703530244900_keaf020-B39","first-page":"1031","article-title":"Clinical and prognostic factors in patients with IgG4-related kidney disease","volume":"18","author":"Chaba","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052703530244900_keaf020-B40","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41598-021-81321-5","article-title":"Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease","volume":"11","author":"Mart\u00edn-Nares","year":"2021","journal-title":"Sci Rep"},{"key":"2025052703530244900_keaf020-B41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pan.2021.03.001","article-title":"Serum free light chain assessment in type 1 autoimmune pancreatitis","volume":"21","author":"Ikemune","year":"2021","journal-title":"Pancreatology"},{"key":"2025052703530244900_keaf020-B42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/key397","article-title":"Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703530244900_keaf020-B43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjd.13296","article-title":"IgG4-related skin disease","volume":"171","author":"Tokura","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025052703530244900_keaf020-B44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2340\/00015555-1707","article-title":"Immunoglobulin G4-related disease associated with cutaneous vasculitis","volume":"94","author":"Kawakami","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2025052703530244900_keaf020-B45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ced.13020","article-title":"A case of leucocytoclastic vasculitis as a complication of IgG4-related skin disease","volume":"42","author":"Nakagawa","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"2025052703530244900_keaf020-B46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ijd.12868","article-title":"Hypocomplementemic urticarial vasculitis arising in a patient with immunoglobulin G4-related disease","volume":"55","author":"Takao","year":"2016","journal-title":"Int J Dermatol"},{"key":"2025052703530244900_keaf020-B47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2023.03.015","article-title":"Association of IgG4-related disease and systemic rheumatic disorders","volume":"111","author":"Batani","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025052703530244900_keaf020-B48","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.autrev.2017.07.020","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome","volume":"16","author":"Danlos","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf020\/61415079\/keaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3701\/61415079\/keaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3701\/61415079\/keaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:53:16Z","timestamp":1748332396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3701\/7951895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf020","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,11]]}}}